Document:

EX-4.1

 Exhibit 4.1 
 REVANCE THERAPEUTICS, INC. 
 AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 
 THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the
“Agreement”) is entered into as of the 29th day of March, 2013, by and among REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”) and certain of the
investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.” 
 RECITALS 
 WHEREAS, certain of the
Investors (the “New Investors”) are purchasing shares of the Company’s Series E-5 Preferred Stock (the “Series E-5 Stock”), pursuant to that certain Amended and Restated Series E-5
Preferred Stock and Warrant Purchase Agreement (the “Purchase Agreement”) dated as of March 29, 2013 and as amended from time to time (the “Financing”); 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this
Agreement; 
 WHEREAS, certain of the Investors (the “Prior Investors”) are
holders of the Company’s Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred Stock, and/or Series D Preferred Stock, which are being
converted into shares of the Company’s Series E-1 Preferred Stock (“Series E-1 Stock”), Series E-2 Preferred Stock (“Series E-2 Stock”), and Series E-3 Preferred Stock
(“Series E-3 Stock”), in accordance with the terms of the Company’s Amended and Restated Certificate of Incorporation filed on or around the date hereof (the “Charter”); 

WHEREAS, certain of the New Investors and/or Prior Investors are also holders of the Company’s Series E-4
Preferred Stock (“Series E-4 Stock” and together with the Series E-5 Stock, Series E-3 Stock, Series E-2 Stock and Series E-1 Stock, the “Preferred Stock”) pursuant to the terms of the conversion of
outstanding convertible promissory notes (the “Note Conversion”) issued in connection with the Company’s Note and Warrant Purchase Agreement dated as of January 24, 2011 and as amended (the “Note Purchase
Agreement”); 
 WHEREAS, the Prior Investors and the Company are parties to an Amended and
Restated Investor Rights Agreement dated December 8, 2009 (the “Prior Agreement”); 

WHEREAS, the New Investors have conditioned the purchase of Series E-5 Stock on the amendment and restatement of
the Prior Agreement on the terms and conditions contained herein; 
 WHEREAS, the parties to the Prior
Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; and 
 WHEREAS, in connection with the consummation of the Financing and the Note Conversion, the parties desire to enter into this Agreement in order to grant the registration rights,
information rights, and other rights as set forth below. 

  
 1. 

 NOW, THEREFORE, in consideration of these premises and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1. GENERAL. 

1.1 Definitions. As used in this Agreement the following terms shall have the following respective meanings: 

(a) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(b) “Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor
or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(c) “Holder” means any person owning of record Registrable Securities that have not been sold to the
public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 
 (d)
“Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act. 

(e) “Intellectual Property Rights” shall mean all of the following: (i) patents, patent applications,
patent disclosures and all related continuation, continuation-in-part, divisional, reissue, re-examination, utility, model, certificate of invention and design patents, patent applications, registrations and applications for registrations, and
(ii) other proprietary rights relating to any of the foregoing (including without limitation associated goodwill and remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions) and
(iii) copies and tangible embodiments thereof. 
 (f) “Register,” “registered,”
and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or
document. 
 (g) “Registrable Securities” means (a) Common Stock of the Company issuable or
issued upon conversion of the Preferred Stock, (b) Common Stock of the Company issuable or issued upon exercise of the warrants issued pursuant to the Note Purchase Agreement or the Purchase Agreement, and (c) any Common Stock of the
Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities.
Notwithstanding the foregoing, Registrable Securities shall not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144, (ii) sold in a private transaction in which the
transferor’s rights under Section 2 of this Agreement are not assigned or (iii) held by a Holder (together with its affiliates) if, as reflected on the Company’s list of stockholders, when the Registrable Securities held by such
Holder (together with any Affiliate of such Holder with whom such Holder must aggregate its sales under Rule 144 of the Securities Act) could be sold without restriction under Rule 144(b)(1) of the Securities Act within a ninety (90) day
period. 

  
 2. 

 (h) “Registrable Securities then outstanding” shall be the
number of shares of the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or convertible securities. 

(i) “Registration Expenses” shall mean all expenses incurred by the Company in complying with
Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements of a single special counsel for the
Holders, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).

 (j) “SEC” or “Commission” means the Securities and Exchange
Commission. 
 (k) “Securities Act” shall mean the Securities Act of 1933, as amended.

 (l) “Selling Expenses” shall mean all underwriting discounts and selling commissions
applicable to the sale. 
 (m) “Shares” shall mean the Company’s Preferred Stock held from
time to time by the Investors listed on Exhibit A hereto and their permitted assigns. 
 (n) “Special
Registration Statement” shall mean (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, including any
registration statements related to the issuance or resale of securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 
 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 
 2.1
Restrictions on Transfer. 
 (a) Each Holder agrees not to make any disposition of all or any portion of the Shares
or Registrable Securities unless and until: 
 (i) there is then in effect a registration statement under the Securities
Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii) (A) The transferee has agreed in writing to be bound by the terms of this Agreement, (B) such Holder shall
have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such Holder shall
have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of
counsel for transactions made pursuant to Rule 144, except in unusual circumstances. After the closing of an Initial Offering that satisfies the criteria set forth in Article IV, Section 5(l)(i)(B) or (C) of the Company’s Charter, the
Company will not require the transferee to be bound by the terms of this Agreement. 
 (b) Notwithstanding the provisions
of subsection (a) above, no such restriction shall apply to a transfer by a Holder (A) to any of its affiliates (as such term is defined in the rules and 

  
 3. 

 
regulations promulgated under the Securities Act and including, but not limited to, an affiliated fund managed by the same manager or managing member or general partner or management company or
by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company, each an “Affiliated Entity”), (B) a partnership transferring to its partners
or former partners in accordance with partnership interests, (C) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (D) a limited liability company transferring
to its members or former members in accordance with their interest in the limited liability company, or (E) an individual transferring to the Holder’s family member or trust for the benefit of an individual Holder; provided that in
each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 
 (c) Each certificate representing Shares or Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with legends
substantially similar to the following (in addition to any legend required under applicable state securities laws): 
 THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER
THE ACT OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT IS AVAILABLE. 
 THE SALE,
PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE
OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (d) The Company shall be obligated to reissue promptly
unlegended certificates at the request of any Holder thereof if the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be
disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any
restrictions hereunder. 
 (e) Any legend endorsed on an instrument pursuant to applicable state securities laws and the
stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 

2.2 Demand Registration. 
 (a) Subject to the conditions of this Section 2.2, if the Company shall receive a written request from the Holders of a majority of the Registrable Securities (the “Initiating
Holders”) that the Company file a registration statement under the Securities Act covering the registration of at least 25% of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price,
net of underwriting discounts and commissions, would exceed $10,000,000), then the 

  
 4. 

 
Company shall, within thirty (30) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 2.2, effect, as
expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered. 
 (b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made
pursuant to this Section 2.2 or any request pursuant to Section 2.4 and the Company shall include such information in the written notice referred to in Section 2.2(a) or Section 2.4(a), as applicable. In such event, the right of
any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent
provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by a majority in
interest of the Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 2.2 or Section 2.4, if the underwriter advises the Company that
marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the
Initiating Holders). Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 
 (c) The Company shall not be required to effect a registration pursuant to this Section 2.2: 
 (i) prior to the earlier of (A) the third anniversary of the date of this Agreement or (B) one hundred eighty (180) days following the effective date of the registration statement
pertaining to the Initial Offering; 
 (ii) after the Company has effected two (2) registrations (other than on
Form S-3 or any equivalent successor form) pursuant to this Section 2.2, and such registrations have been declared or ordered effective; 
 (iii) during the period starting with the date of filing of, and ending on the date one hundred eighty (180) days following the effective date of the registration statement pertaining to a
public offering, other than pursuant to a Special Registration Statement; provided that the Company makes reasonable good faith efforts to cause such registration statement to become effective and provided, in the case of a public offering
other than the Initial Offering, that the Initiating Holders were permitted to register such shares as requested to be registered pursuant to Section 2.3 hereof without reduction by the underwriter thereof; provided that for this
purpose, a withdrawn registration will not count unless it has been closed or withdrawn by the Investors (other than as a result of a material adverse change to the Company); 
 (iv) if within thirty (30) days of receipt of a written request from Initiating Holders pursuant to Section 2.2(a), the Company gives notice to the Holders of the Company’s intention
to file a registration statement for a public offering, other than pursuant to a Special Registration Statement within ninety (90) days; 

  
 5. 

 (v) if the Company shall furnish to Holders requesting a registration statement
pursuant to this Section 2.2, a certificate signed by the Chairman of the Board of Directors of the Company (the “Board”) stating that in the good faith judgment of the Board, it would be seriously detrimental to the
Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the
Initiating Holders; provided that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; 
 (vi) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.4
below; or 
 (vii) in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 
 2.3 Piggyback
Registrations. 
 (a) The Company shall notify all Holders of Registrable Securities in writing at least thirty
(30) days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of
securities of the Company, but excluding Special Registration Statements and registration statements relating to an Initial Offering) and will afford each such Holder an opportunity to include in such registration statement all or part of such
Registrable Securities held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within fifteen (15) days after the above-described notice from the
Company, so notify the Company in writing. Such notice shall state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement
thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to
offerings of its securities, all upon the terms and conditions set forth herein. 
 (b) Underwriting. If the registration
statement under which the Company gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to be included in a
registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All
Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding
any other provision of this Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be
allocated, first, to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata
basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below thirty percent (30%) of the total amount of securities included in such registration, unless such
offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding
clause. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by 

  
 6. 

 
written notice to the Company and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or
withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership or corporation, the partners, retired partners and stockholders of such Holder, or the estates and family members of any
such partners and retired partners and any trusts for the benefit of any of the foregoing person shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the
aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 
 (c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 prior to the effectiveness of such
registration whether or not any Holder has elected to include securities in such registration, and shall promptly notify any Holder that has elected to include shares in such registration of such termination or withdrawal. The Registration Expenses
of such withdrawn registration shall be borne by the Company in accordance with Section 2.5 hereof. 
 2.4 Form S-3
Registration. In case the Company shall receive from any Holder or Holders of Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar
short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders
of Registrable Securities; and 
 (b) as soon as practicable, effect such registration and all such qualifications and
compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion
of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the
Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i) if Form S-3 is not available for such offering by the Holders, or 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration,
propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than five million dollars ($5,000,000), or 
 (iii) if within thirty (30) days of receipt of a written request from any Holder or Holders pursuant to this Section 2.4, the Company gives notice to such Holder or Holders of the
Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement; 
 (iv) if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the
Company and its stockholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than ninety
(90) days after receipt of the request of the Holder or Holders under this Section 2.4; provided, that the right to delay a request under Section 2.2(c)(v) and this 

  
 7. 

 
Section 2.4(b)(iv) shall be exercised by the Company not more than once in any twelve (12) month period, 
 (v) if the Company has, within the twelve (12) month period preceding the date of such request, already effected two (2) registration statements on Form S-3 for the Holders pursuant to
Section 2.4, or 
 (vi) in any particular jurisdiction in which the Company would be required to qualify to do
business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c) Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the Registrable Securities
and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for registration or registrations
effected pursuant to Section 2.2. 
 2.5 Expenses of Registration. Except as specifically provided herein, all
Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Section 2.2 or any registration under Section 2.3 or Section 2.4 herein shall be borne by the Company. All Selling Expenses
incurred in connection with any registrations hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay for
expenses of any registration proceeding begun pursuant to Section 2.2 or 2.4, the request of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning
the Company of which the Initiating Holders were not aware at the time of such request or (b) the Holders of a majority of Registrable Securities agree to forfeit their right to one requested registration pursuant to Section 2.2 or
Section 2.4, as applicable, in which event such right shall be forfeited by all Holders). If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including Registrable Securities)
requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to clause (a) above, then the Holders shall
not forfeit their rights pursuant to Section 2.2 or Section 2.4 to a demand registration. 
 2.6 Obligations of the
Company. Whenever required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and,
upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to one hundred eighty (180) days or, if earlier, until the Holder or Holders have completed the
distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may
delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration
statement during the Suspension Period) if the Board reasonably believes that there is or may be in existence material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the
registration statement could result in a Violation (as defined below). In the event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the
registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period. The 

  
 8. 

 
Company may extend the Suspension Period for an additional consecutive thirty (30) days with the consent of the holders of a majority of the Registrable Securities registered under the
applicable registration statement, which consent shall not be unreasonably withheld. No more than one (1) such Suspension Period shall occur in any twelve (12) month period. If so directed by the Company, all Holders registering shares
under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after receiving notice of such delay or suspension;
and (ii) use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at
the time of receipt of such notice. The Company shall not be required to file, cause to become effective or maintain the effectiveness of any registration statement that contemplates a distribution of securities on a delayed or continuous basis
pursuant to Rule 415 under the Securities Act. Any suspension with this Section 2.6(a) shall be in lieu of, and not in addition to, any filing delay pursuant to Sections 2.2(c)(v) or 2.4(b)(iv). 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in
subsection (a) above and comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement in accordance with the sellers’ intended method of disposition
set forth in such registration statement. 
 (c) Furnish to the Holders such number of copies of a prospectus, including
a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use its reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions (unless the Company is already subject to service in any such jurisdiction and except as may be required by the Securities Act). 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in
usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company will use reasonable efforts to amend or supplement such prospectus in order
to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then
existing. 
 (g) Use its reasonable efforts to furnish, on the date that such Registrable Securities are delivered to the
underwriters for sale, if such securities are being sold through underwriters, (i) an 

  
 9. 

 
opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten
public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public
accountants to underwriters in an underwritten public offering addressed to the underwriters. 
 (h) Make available for
inspection by each Holder of Registrable Securities covered by such registration statement, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such
seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors and employees to
supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration, provided, however, that the Company shall be under no obligation to disclose to any party
information which it deems to be sensitive or confidential in nature and not otherwise required to be disclosed in the opinion of counsel to the Company, and provided further that if, in the good faith belief of the Company or its counsel,
such disclosure would potentially violate the rules and regulations promulgated under the Securities Act of 1933, as amended, or the Exchange Act, as amended, including any rules or interpretations set forth by the Commission or any applicable
trading exchange (including Nasdaq), it may notify the seller, underwriter, attorney or accountant of such belief and shall be under no further obligation with regard to disclosure of or access to the requested subject matter. 

(i) Cooperate with the Holders and the managing underwriters, if any, to facilitate the timely preparation and delivery of
certificates representing Registrable Securities to be sold, such certificates to be in such denominations and registered in such names as such Holders or the managing underwriters may request at least five business days prior to any sale of
Registrable Securities. 
 2.7 Delay of Registration; Furnishing Information. 

(a) No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the
result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

(b) It shall be a condition precedent to the obligations of the Company to take any action pursuant to Section 2.2, 2.3 or
2.4 that the selling Holders furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to effect the registration of their
Registrable Securities. 
 (c) The Company shall have no obligation with respect to any registration requested pursuant
to Section 2.2 or Section 2.4 if, due to the operation of subsection 2.2(b), the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed
the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under Sections 2.2, 2.3
or 2.4: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners,
members, officers and directors of each Holder, any underwriter (as defined in 

  
 10.

 
the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims,
damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of
or are based upon any of the following statements, omissions or violations (collectively a “Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such
registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material
fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or
regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, member, officer,
director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that the indemnity
agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder. 

(b) To the extent permitted by law, each Holder will severally and not jointly, if Registrable Securities held by such Holder are
included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who controls the Company within the
meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors or officers or any person who controls such Holder, against any losses,
claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or controlling person of such other Holder may become subject
under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements: (i) any untrue
statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto,
(ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities
Act (collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an
instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer,
controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined
that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that in no event shall any indemnity under this Section 2.8 exceed the net proceeds from the offering received
by such Holder. 

  
 11.

 (c) Promptly after receipt by an indemnified party under this Section 2.8 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.

 (d) If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law
contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying party
and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, that in no event shall any contribution
by a Holder hereunder exceed the net proceeds from the offering received by such Holder. 
 (e) The obligations of the
Company and Holders under this Section 2.8 shall survive completion of any offering of Registrable Securities in a registration statement and the termination of this Agreement. No indemnifying party, in the defense of any such claim or
litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability in respect to such claim or litigation. 
 2.9 Assignment of Registration Rights.
The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that
(a) is a subsidiary, parent, general partner, limited partner, retired partner, manager or retired manager, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company (and in the case of
a Holder that is a U.S. limited partnership, current and former limited partners, general partners, managers, members and principals of such Holder or any general partner of such Holder), (b) is a Holder’s family member or trust for the
benefit of an individual Holder, (c) acquires at least one hundred thousand (100,000) shares of Registrable Securities (as adjusted for stock splits and combinations); or (d) is an entity affiliated by common control (or other related
entity including, without limitation, an Affiliated Entity) with such Holder, provided, however, (i) the transferor shall, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of
such 

  
 12.

 
transferee or assignee and the securities with respect to which such registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth
in this Agreement. 
 2.10 Limitation on Subsequent Registration Rights. Other than as provided in Section 5.10,
after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder (i) rights to demand the registration of their shares, or to
include their shares in a registration statement that would reduce the number of shares includable by the Holders or (ii) any other registration rights senior to those granted to the Holders hereunder, other than the right to a Special
Registration Statement. 
 2.11 “Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall
not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to, any Common Stock (or other securities) of the Company held by
such Holder (other than those included in the registration) (i) during the 180-day period following the effective date of the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the
underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation), and (ii) during the 90-day period following the effective date of a
registration statement of the Company filed under the Securities Act other than for the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 90-day period, as the underwriters or the Company shall request in
order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation); provided, that, with respect to (i) and (ii) above, all officers and directors of the Company are bound by and have
entered into similar agreements. The obligations described in this Section 2.11 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a
registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. Except to the extent approved by the holders of a majority of the then outstanding Registrable Securities, the Company agrees that it
shall not release any Holder (or any officer or director referred to hereinabove) from the obligations imposed pursuant to this Section 2.11 unless all Holders are so released on a proportionate basis relative to their ownership of Registrable
Securities. 
 2.12 Agreement to Furnish Information. Each Holder agrees to execute and deliver such other agreements as
may be reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. In addition, if requested by the Company or the
representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection
with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in Section 2.11 and this Section 2.12 shall not apply to a Special
Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. Each
Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the Company’s stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the
right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 2.13 Rule 144 Reporting.
With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to:

  
 13.

 (a) Make and keep public information available, as those terms are understood and
defined in SEC Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public;

 (b) File with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange
Act; and 
 (c) So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon request: a
written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time when it so qualifies); a copy of the most recent annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may
reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell any such securities without registration. 
 2.14 Changes in Common Stock or Preferred Stock. If, and as often as, there is any change in the Common Stock or the Shares by way of a stock split, stock dividend, combination or reclassification,
or through a merger, consolidation, reorganization or recapitalization in which the holders of 80% of the Company’s capital stock prior to such merger, consolidation, reorganization or recapitalization continue to hold at least 80% of the
Company’s capital stock following such merger, consolidation, reorganization or recapitalization, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall continue with respect to the
Common Stock or the Shares as so changed. 
 SECTION 3. COVENANTS OF THE COMPANY. 

3.1 Basic Financial Information and Reporting. 
 (a) The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and
administered in accordance with generally accepted accounting principles consistently applied, and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently
applied. 
 (b) So long as an Investor (with its affiliates), shall own at least twelve and one half percent
(12.5%) of the outstanding shares of Series E-1 Stock, twelve percent and one half percent (12.5%) of the outstanding shares of Series E-2 Stock (or in the case of Shepherd Ventures II, L.P. (“Shepherd”) and Palo
Alto Fund II, L.P., so long as such Investor holds shares of Preferred Stock having an aggregate original issue price of at least $499,000), twelve and one half percent (12.5%) of the outstanding shares of Series E-3 Stock, twelve and one half
percent (12.5%) of the outstanding shares of Series E-4 Stock or twelve and one half percent (12.5%) of the outstanding shares of Series E-5 Stock (each, a “Major Investor”), the Company will furnish each such Major
Investor: (i) at least thirty (30) days prior to the beginning of each fiscal year or as soon as practicable, an annual budget and operating plans for such fiscal year (and as soon as available, any subsequent written revisions thereto),
in form and substance reasonably acceptable to the Major Investors; and (ii) as soon as practicable after the end of each quarter, and in any event within thirty (30) days thereafter, a balance sheet of the Company as of the end of each
such quarter, and a statement of income and a statement of cash flows of the Company for such quarter and for the current fiscal year to date, including a comparison to plan figures for such period, prepared in accordance with generally accepted
accounting principles consistently applied, with the 

  
 14.

 
exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 
 (c) As soon as practicable after the end of each fiscal year of the Company, and in any event within ninety (90) days thereafter, the Company will furnish each Major Investor an audited
balance sheet of the Company, as at the end of such fiscal year, and an audited statement of income and statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently
applied and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion thereon by independent public accountants of
national standing selected by the Board, or the audit committee thereof. 
 3.2 Inspection Rights. Each Major Investor
shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information
as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to a competitor of the Company or with
respect to information which the Board determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed. 
 3.3 Confidentiality of Records. Each Investor agrees to use the same degree of care as such Investor uses to protect its own confidential information to keep confidential any information furnished
to such Investor that the Company identifies as being confidential or proprietary (so long as such information is not in the public domain), except that such Investor may disclose such proprietary or confidential information (i) to any partner,
subsidiary or parent of such Investor for the purpose of evaluating its investment in the Company as long as such partner, subsidiary or parent is advised of the confidentiality provisions of this Section 3.3; (ii) at such time as it
enters the public domain through no fault of such Investor; (iii) that is communicated to it free of any obligation of confidentiality; (iv) that is developed by Investor or its agents independently of and without reference to any
confidential information communicated by the Company; or (v) as required by applicable law; and provided, further, that any Investor may provide financial information to its partners or members as required by any partnership agreement or
limited liability operating agreement. 
 3.4 Director and Officer Insurance. The Company will use its best efforts to
obtain and maintain in full force and effect director and officer liability insurance with terms reasonably satisfactory to the Investors and the Board. 
 3.5 Reservation of Common Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable
from time to time upon such conversion. 
 3.6 Stock Vesting. Unless otherwise approved by a majority of the Board, all
stock options and other stock equivalents issued after the date of this Agreement to employees, directors, consultants and other service providers shall be subject to vesting over a four year period as follows: (a) twenty-five percent
(25%) of such stock shall vest at the end of the first year following the earlier of the date of issuance or such person’s services commencement date with the company, and (b) seventy-five percent (75%) of such stock shall vest
over the remaining three (3) years. 
 3.7 Proprietary Information and Inventions Agreement. The Company shall
require all employees and consultants to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form approved by the Board. 

  
 15.

 3.8 Qualified Small Business. For so long as any of the Shares are held by an
Investor (or a transferee in whose hands such Shares are eligible to qualify as “Qualified Small Business Stock” as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended (the “Code”)), the
Company will use its reasonable efforts to comply with the reporting and recordkeeping requirements of Section 1202 of the Code, any regulations promulgated thereunder and any similar state laws and regulations. 

3.9 Directors’ Liability and Indemnification. The Charter and Bylaws shall provide (a) for elimination of the liability
of director to the maximum extent permitted by law and (b) for indemnification of directors for acts on behalf of the Company to the maximum extent permitted by law. 
 3.10 Preservation of Corporate Existence. The Company shall use its commercially reasonable efforts to preserve and maintain, and cause each Subsidiary to preserve and maintain, its corporate
existence, rights, franchises and privileges in the jurisdiction of its incorporation, and qualify and remain qualified, and cause each Subsidiary to qualify and remain qualified, as a foreign corporation in each jurisdiction in which such
qualification is necessary or desirable in view of its business and operations or their ownership or lease of its properties. 

3.11 Maintenance of Properties. The Company shall use its commercially reasonable efforts to maintain and preserve, and cause each
Subsidiary to maintain and preserve, all of its properties and assets, necessary for the proper conduct of its business, in good repair, working order and condition, ordinary wear and tear excepted. 

3.12 Payment of Taxes. The Company shall pay and discharge, and cause each Subsidiary to pay and discharge, all taxes,
assessments, and governmental charges or levies imposed upon it or upon its income, profits or business, or upon any properties belonging to it, prior to the date on which material penalties attach thereto, and all lawful claims which, if unpaid
might become a material lien or charge upon any properties of the Company, provided that neither the Company nor any Subsidiary shall be required to pay any such tax, assessment, charge, levy or claim which is being contested in good faith and by
appropriate proceedings if the Company or any Subsidiary shall have set aside on its books sufficient reserves, if any, with respect thereto. 
 3.13 Increase in Size of Authorized Shares under Equity Incentive Plan. The Company shall not increase the number of authorized shares issuable under the Company’s equity incentive plans in
excess of 5,084,877 shares (as adjusted for stock splits and combinations) without the approval of a majority of the Board, nor shall the Company issue shares of Common Stock, or options to purchase Common Stock, to employees of or consultants to
the Company or any of its subsidiaries or affiliates other than pursuant to such plans without the approval of a majority of the Board. 
 3.14 Certain Covenants Relating to SBA Matters. 
 (a) Use of
Proceeds. The proceeds from the issuance and sale of the Series E-5 Stock pursuant to the Purchase Agreement (the “Proceeds”) shall not be used to redeem shares of capital stock of the Company. The Company shall provide
each Investor which is a licensed Small Business Investment Company (an “SBIC Investor”) and the Small Business Administration (the “SBA”) reasonable access to the Company’s books and records for
the purpose of confirming the use of Proceeds. 
 (b) Business Activity. For a period of one year following the Second
Closing under the Purchase Agreement the Company shall not change the nature of its business activity if such change would render the Company ineligible as provided in 13 C.F.R. Section 107.720. 

  
 16.

 (c) Compliance. So long as any SBIC Investor holds any securities of the Company, the
Company will at all times comply with the non-discrimination requirements of 13 C.F.R. Parts 112, 113 and 117. 

(d) Information for SBIC Investor. At such other times as an SBIC Investor may reasonably request, the Company shall deliver to
such SBIC Investor a written assessment, in form and substance satisfactory to such SBIC Investor, of the economic impact of such SBIC Investor’s financing specifying the full-time equivalent jobs created or retained in connection with such
investment, and the impact of the financing on the Company’s business in terms of profits and on taxes paid by the Company and its employees. Upon request, the Company agrees to promptly provide each SBIC Investor with sufficient information to
permit such Investor to comply with their obligations under the Small Business Investment Act of 1958, as amended, and the regulations promulgated thereunder and related thereto; provided, however, each SBIC Investor agrees that it will
protect any information which the Company labels as confidential to the extent permitted by law. Any submission of any financial information under this Section shall include a certificate of the Company’s president, chief executive officer or
chief financial officer. 
 3.15 Board Observation Rights. 

(a) For so long as Shepherd is a Major Investor, the Company shall allow one representative designated by Shepherd (the
“Shepherd Representative”) to attend all meetings of the Board and committees thereof in a nonvoting capacity, and in connection therewith, the Company shall deliver to the Shepherd Representative, concurrently with the
delivery to the directors, copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to the Board or members of any committees thereof (the “Materials”); provided,
however, that the Company reserves the right to exclude the Shepherd Representative from access to any Materials or meeting or portion thereof if the Board determines in good faith upon advice of counsel that such exclusion is reasonably necessary
to preserve the attorney-client privilege. The decision of the Board with respect to the privileged nature of such information shall be final and binding. 
 (b) For so long as Essex Woodlands Health Ventures Fund VIII, L.P. (together with its affiliates, including its Affiliated Entities, in the aggregate) (“Essex”) is a Major
Investor, at any time there is no individual designated by Essex serving on the Board, the Company shall allow one representative designated by Essex (the “Essex Representative”) to attend all meetings of the Board and
committees thereof in a nonvoting capacity, and in connection therewith, the Company shall deliver the Materials to the Essex Representative, concurrently with the delivery to the directors; provided, however, that the Company reserves the right to
exclude the Essex Representative from access to any Materials or meeting or portion thereof if the Board determines in good faith upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege. The
decision of the Board with respect to the privileged nature of such information shall be final and binding. 
 (c) For so
long as Essex Capital Corporation (collectively with its designees, “Essex Capital”) is a Major Investor, at any time there is no individual designated by Essex Capital serving on the Board, the Company shall allow one
representative designated by Essex Capital (the “Essex Capital Representative”) to attend all meetings of the Board and committees thereof in a nonvoting capacity, and in connection therewith, the Company shall deliver the
Materials to the Essex Capital Representative, concurrently with the delivery to the directors; provided, however, that the Company reserves the right to exclude the Essex Capital Representative from access to any Materials or meeting or portion
thereof if the Board determines in good faith upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege. The decision of the Board with respect to the privileged nature of such information shall be
final and binding. Notwithstanding Section 3.1(b), Essex Capital shall be 

  
 17.

 
deemed a “Major Investor” under this Agreement so long as Essex Capital holds shares of Company Preferred Stock having an aggregate original issue price of at least $2,999,998 (as
adjusted for stock splits, combinations and the like). 
 3.16 Committee Rights. Each standing committee of the Board
shall include at least one director elected by the holders of the Company’s Series E-5 Preferred Stock as a member of such committee. 
 3.17 Amended and Restated Certificate of Incorporation. Promptly following the Second Closing (as defined in the Purchase Agreement), the Company and the Investors shall take such actions as are
necessary to file an amended and restated certificate of incorporation eliminating the Prior Preferred (as defined in the Charter). 
 3.18 Termination of Covenants. All covenants of the Company contained in Section 3 of this Agreement (other than the provisions of Sections 3.3) shall expire and terminate as to each Investor
upon the earlier of (i) the closing of an Initial Offering that satisfies the criteria set forth in Article IV, Section 5(l)(i) of the Charter (other than the provisions of Section 3.1(a) and Sections 3.5 through 3.14, which shall
expire only upon an Initial Offering that satisfies the criteria set forth in Article IV, Section 5(l)(i)(B) or (C) of the Charter), (ii) upon an “Asset Transfer” or “Acquisition”, each
as defined in the Company’s Charter (a “Change of Control”) or (iii) upon a liquidation, dissolution or winding up of the Company. 
 SECTION 4. RIGHTS OF FIRST REFUSAL. 
 4.1 Subsequent Offerings.
Subject to applicable securities laws, each Major Investor shall have a right of first refusal to purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue
after the date of this Agreement, other than the Equity Securities excluded by Section 4.6 hereof. Each Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including
all shares of Common Stock issuable or issued upon conversion of the Shares) which such Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s
outstanding Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities. The term
“Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common
Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security or
(iv) any such warrant or right. 
 4.2 Exercise of Rights. If the Company proposes to issue any Equity Securities,
it shall give each Major Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each Major Investor shall have fifteen (15) days from
the giving of such notice to agree to purchase its pro rata share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of
Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Major Investor who would cause the Company to be in violation of applicable federal securities laws by
virtue of such offer or sale. 

  
 18.

 4.3 Issuance of Equity Securities to Other Persons. If not all of the Major Investors
elect to purchase their pro rata share of the Equity Securities, then the Company shall promptly notify in writing the Major Investors who do so elect and shall offer such Major Investors the right to acquire such unsubscribed shares. The
Major Investors shall have five (5) days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares. If the Major Investors fail to exercise in full the rights of first
refusal, the Company shall have ninety (90) days thereafter to sell the Equity Securities in respect of which the Major Investor’s rights were not exercised, at the same price and upon the same general terms and conditions specified in the
Company’s notice to the Major Investors pursuant to Section 4.2 hereof. If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section 4.2, the Company shall not thereafter
issue or sell any Equity Securities, without first offering such securities to the Major Investors in the manner provided above. 
 4.4 Termination and Waiver of Rights of First Refusal. The rights of first refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the
closing of an Initial Offering that satisfies the criteria set forth in Article IV, Section 5(l)(i)(B) or (C) of the Charter or (ii) a Change in Control. Notwithstanding Section 5.5 hereof, the rights of first refusal established
by this Section 4 may be amended, or any provision waived with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities held by all Major Investors, or as permitted by Section 5.5.

 4.5 Transfer of Rights of First Refusal. The rights of first refusal of each Major Investor under this Section 4
may be transferred to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.9. 
 4.6 Excluded Securities. The rights of first refusal established by this Section 4 shall have no application to any of the following Equity Securities: 

(a) up to 5,084,877 shares of Common Stock and/or options, warrants or other Common Stock purchase rights, or such greater amount
approved by the Board pursuant to Section 3.13, and the Common Stock issued pursuant to such options, warrants or other rights issued or to be issued to employees, officers or directors of, or consultants or advisors to the Company or any
subsidiary, pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board of Directors; 

(b) stock issued or issuable pursuant to any rights or agreements, options, warrants or convertible securities outstanding as of
the date of this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first refusal established by this Section 4 were complied with, waived, or were
inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the Company of such rights or agreements; 
 (c) any Equity Securities issued for consideration other than cash pursuant to a merger, consolidation, strategic alliance, acquisition or similar business combination approved by two-thirds of the
members of the Board of Directors; 
 (d) any Equity Securities issued in connection with any stock split, stock dividend
or recapitalization by the Company; 
 (e) any Equity Securities issued pursuant to any equipment loan or leasing
arrangement, real property leasing arrangement, or debt financing from a bank or similar financial or lending institution approved by the Board of Directors, and Equity Securities issued in connection with that certain Note Purchase Agreement;

  
 19.

 (f) any Equity Securities that are issued by the Company pursuant to a registration
statement filed under the Securities Act; 
 (g) any Equity Securities issued in connection with strategic transactions
involving the Company and other entities, including (i) joint ventures, manufacturing, marketing, licensing or distribution arrangements or (ii) technology transfer or development arrangements; provided that the issuance of shares
therein has been approved by two-thirds of the members of the Board of Directors; and 
 (h) any Equity Securities issued
by the Company pursuant to the terms of the Purchase Agreement. 
 SECTION 5. MISCELLANEOUS. 

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California in all respects as
such laws are applicable to agreements among California residents entered into and to be performed entirely within California. The parties agree that any action brought by either party under or in relation to this Agreement, including without
limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of Santa Clara, California.

 5.2 Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the
benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable Securities
from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem and treat the
person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3 Entire Agreement. This Agreement, the Exhibits and Schedules hereto, the Purchase Agreement and the other documents delivered
pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties,
covenants and agreements except as specifically set forth herein and therein. 
 5.4 Severability. In the event one or
more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this
Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
 5.5
Amendment and Waiver. 
 (a) Except as otherwise expressly provided, this Agreement may be amended or modified only
upon the written consent of the Company and the Investors holding a majority of the Preferred Stock (on an as converted to Common Stock basis) and Common Stock issued on conversion of the Preferred Stock (voting together as a single class on an as
converted to Common Stock basis) held by all Investors. 
 (b) Except as otherwise expressly provided, the obligations of
the Company and the rights of the Holders under this Agreement may be waived only with the written consent of the Investors 

  
 20.

 
holding a majority of the Preferred Stock (on an as converted to Common Stock basis) and Common Stock issued on conversion of the Preferred Stock (voting together as a single class on an as
converted to Common Stock basis) held by all Investors. 
 (c) For the purposes of determining the number of Holders or
Investors entitled to vote or exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company. 

5.6 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party,
upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of
any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or
any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or
otherwise afforded to any party, shall be cumulative and not alternative. 
 5.7 Notices. All notices required or
permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the
recipient; if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at such other
address or electronic mail address as such party may designate by ten (10) days advance written notice to the other parties hereto. 
 5.8 Attorneys’ Fees. In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable
fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 5.9 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

5.10 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares
of its Preferred Stock pursuant to the Purchase Agreement, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be
deemed an “Investor,” a “Holder” and a party hereunder. Notwithstanding anything to the contrary contained herein, if the Company shall issue Equity Securities in accordance with Section 4.6 (c),
(e) or (g) of this Agreement, any purchaser of such Equity Securities may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an
“Investor,” a “Holder” and a party hereunder. 
 5.11 Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed by signatures delivered by e-mail or facsimile. 

  
 21.

 5.12 Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities or persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or
neutral, singular or plural, as to the identity of the parties hereto may require. 
 5.14 Termination. This Agreement
shall terminate and be of no further force or effect upon the earlier of (i) three (3) years following the Company’s Initial Offering that satisfies the criteria set forth in Article IV, Section 5(l)(i)(B) or Article IV,
Section 5(l)(i)(C) of the Company’s Charter, (ii) an Acquisition or Asset Transfer as defined in the Company’s Amended Certificate of Incorporation, or (iii) a liquidation, dissolution or winding up of the Company.

 5.15 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated
herein. Such amendment and restatement is effective upon the execution of the Agreement by the Company and the holders of a majority in interest of the Registrable Securities held by the Prior Investors outstanding as of the date of this Agreement.
Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect, including, without limitation, all rights of
first refusal and any notice period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement. Each of the Prior Investors acknowledge and agree that the execution and delivery by the Company of this
Agreement, the Purchase Agreement and the additional Related Agreements and the performance by the Company of its obligations thereunder do not constitute a default under the provisions of the Prior Agreement. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 22.

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	COMPANY:
	
	REVANCE THERAPEUTICS, INC.
		
	By:	 	 /s/ L. Daniel Browne

		 	L. Daniel Browne,
		 	President and Chief Executive Officer
		
		 	2400 Bayshore Parkway, Suite 100
		 	Mountain View, CA 94043

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	ASANA HOLDINGS, LLC
		
	By:	 	 /s/ John H. Perry III

		
	Print Name:	 	 John H. Perry III

		
	Title:	 	 Managing Member

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	CNF INVESTMENTS II, LLC
		
	By:	 	 /s/ Robert J. Flanagan

		
	Print Name:	 	 Robert J. Flanagan

		
	Title:	 	 Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
					
	INVESTORS:
	
	DELPHI VENTURES VIII, L.P.
		
	By:	 	Delphi Management Partners VIII, LLC,
		 	its General Partner
		
	By:	 	 /s/ David L. Douglass

		 	Name:	 	David L. Douglass
		 	Title:	 	Managing Member
	
	DELPHI BIOINVESTMENTS VIII, L.P.
		
	By:	 	Delphi Management Partners VIII, LLC,
		 	its General Partner
		
	By:	 	 /s/ David L. Douglass

		 	Name:	 	David L. Douglass
		 	Title:	 	Managing Member

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ Douglas Mansfield Petty

	DOUGLAS MANSFIELD PETTY

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	ESSEX WOODLANDS HEALTH VENTURES FUND V, L.P.
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES V, LLC
	ITS:	 	GENERAL PARTNER

 
			
		
	Signature:	 	 /s/ Phyllis Gardner

		
	Print Name:	 	 Phyllis Gardner

		
	Title:	 	 Partner

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
	ITS:	 	GENERAL PARTNER
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
	ITS:	 	GENERAL PARTNER

 
			
		
	By:	 	 /s/ Ron Eastman

		
	Print Name:	 	 Ron Eastman

		
	Title:	 	 Manager

			
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
	ITS:	 	GENERAL PARTNER
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
	ITS:	 	GENERAL PARTNER

 
			
		
	By:	 	 /s/ Ron Eastman

		
	Print Name:	 	 Ron Eastman

		
	Title:	 	 Manager

			
	
	ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.
	ITS:	 	GENERAL PARTNER
		
	BY:	 	ESSEX WOODLANDS HEALTH VENTURES VIII, LLC
	ITS:	 	GENERAL PARTNER

 
			
		
	By:	 	 /s/ Ron Eastman

		
	Print Name:	 	 Ron Eastman

		
	Title:	 	 Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	WILLIAM FACTEAU AND LYDIA FACTEAU, TRUSTEES OF
THE FACTEAU REVOCABLE TRUST DATED MARCH 3, 2009
		
	Signature:	 	 /s/ Bill Facteau

		
	Print Name:	 	 Bill Facteau

		
	Title:	 	  

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ Geoffrey and Annette Grant

	GEOFFREY AND ANNETTE GRANT

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
					
	INVESTORS:
	
	NOVAQUEST PHARMA OPPORTUNITIES FUND III, L.P.
		
	By:	 	Its General Partner, NQ HCIF General Partner, L.P.
	By:	 	Its General Partner, NQ HCIF GP, LTD.
		
	By:	 	 /s/ John Bradley

		 	Name:	 	John Bradley
		 	Title:	 	Senior Partner and Director

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	PALO ALTO FUND II, L.P.
		
	BY:	 	PALO ALTO INVESTORS, LLC.
	BY:	 	GENERAL PARTNER
		
	BY:	 	PALO ALTO INVESTORS, MANAGER
	
	 /s/ Scott R. Smith

	Scott R. Smith
	Chief Operating Officer

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	SHEPHERD VENTURES II, L.P.
		
	BY:	 	SHEPHERD MANAGEMENT, L.L.C.
	BY:	 	GENERAL PARTNER
	
	 /s/ Richard P. Kuntz

	Richard P. Kuntz
	Managing Director

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	TECHNOLOGY PARTNERS FUND VII, L.P.
		
	BY:	 	TP MANAGEMENT VII, L.L.C.
		
	By:	 	 /s/ James Glasheen, Ph.D.

		 	Managing Member
	
	TECHNOLOGY PARTNERS AFFILIATES VII, L.P.
		
	BY:	 	TP MANAGEMENT VII, L.L.C.
		
	By:	 	 /s/ James Glasheen, Ph.D.

		 	Managing Member

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	VCA-RTI PARTNERSHIP
		
	By:	 	ACH Management, LLC
	Its:	 	Managing Partner.
	
	 /s/ Oscar Haynes Morris, Jr.

	Oscar Haynes Morris, Jr.
	Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	BIOTECHNOLOGY DEVELOPMENT FUND IV, L.P.
		
	BY:	 	BIOASIA INVESTMENTS IV, LLC
	ITS:	 	GENERAL PARTNER
	
	 /s/ Frank Kung

	Frank Kung
	Managing Partner
	
	BIOTECHNOLOGY DEVELOPMENT FUND IV AFFILIATES, L.P.
		
	BY:	 	BIOASIA INVESTMENTS IV, LLC
	ITS:	 	GENERAL PARTNER
	
	 /s/ Frank Kung

	Frank Kung
	Managing Partner
	
	BDF IV ANNEX FUND, L.P.
		
	BY:	 	BIOASIA INVESTMENTS IV, LLC
	ITS:	 	GENERAL PARTNER
	
	 /s/ Frank Kung

	Frank Kung
	Managing Partner

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ David Styka

	DAVID STYKA

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	DAN AND BRENDA BROWNE LIVING TRUST
		
	Signature:	 	  

		
	Print Name:	 	  

		
	Title:	 	  

	
	 /s/ L. Daniel Browne

	L. DANIEL BROWNE

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ Michael D. Dake, M.D.

	MICHAEL D. DAKE, M.D.

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	SHAH INVESTORS, LP
		
	Signature:	 	 /s/ Mahendra Shah

		
	Print Name:	 	 Mahendra Shah

		
	Title:	 	 Managing Partner

	
	 /s/ L. Daniel Browne

	L. DANIEL BROWNE

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ Lisa Perry

	LISA PERRY

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	KUNG FAMILY TRUST DATED 02/08/02
		
	Signature:	 	 /s/ Frank Kung

		
	Print Name:	 	 Frank Kung

		
	Title:	 	Trustee

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	 /s/ Christopher C. Dewey

	CHRISTOPHER C. DEWEY

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	ESSEX CAPITAL CORPORATION
		
	Signature:	 	 /s/ Ralph T. Iannelli

		
	Print Name:	 	 Ralph T. Iannelli

		
	Title:	 	 President

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	BSYE LLC
		
	Signature:	 	 /s/ Ralph T. Iannelli

		
	Print Name:	 	 Ralph T. Iannelli

		
	Title:	 	 Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	SVB FINANCIAL GROUP
		
	Signature:	 	 /s/ Scott Newman

		
	Print Name:	 	 Scott Newman

		
	Title:	 	 Portfolio and Funding Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	 /s/ Kevin Knight

	KEVIN TYLER KNIGHT
	
	KNIGHT MARKETING COMMUNICATIONS INC. DEFINED BENEFIT PENSION
PLAN
		
	Signature:	 	 /s/ Kevin Knight

		
	Print Name:	 	 Kevin Knight

		
	Title:	 	  

	
	 /s/ Kelsey Margaret Knight

	KELSEY MARGARET KNIGHT
	
	 /s/ Tyler Phillips Knight

	TYLER PHILLIPS KNIGHT

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	LIGHTHOUSE CAPITAL PARTNERS IV, L.P.
	
	By: Lighthouse Management Partners IV, L.L.C.
	Its: Managing Partner
	
	 /s/ Thomas Conneely

	Name:	 	Thomas Conneely
	Title:	 	Vice President
	
	LIGHTHOUSE CAPITAL PARTNERS V, L.P.
	
	By: Lighthouse Management Partners V, L.L.C.
	Its: Managing Partner
	
	 /s/ Thomas Conneely

	Name:	 	Thomas Conneely
	Title:	 	Vice President

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	LEADER LENDING, LLC – SERIES A
	
	 By: Leader Ventures, LLC
        Its Investment Manager

	
	 /s/ Robert W Molke

	Name:	 	Robert W Molke
	Title:	 	Managing Director
	
	LEADER LENDING, LLC – SERIES B
	
	 By: Leader Ventures, LLC
        Its Investment Manager

	
	 /s/ Robert W Molke

	Name:	 	Robert W Molke
	Title:	 	Managing Director

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	INVESTORS:
	
	HORIZON CREDIT I LLC
	By: Compass Horizon Fund Company LLC, its sole member
	By: Horizon Technology Finance Corporation, its sole member
	
	 /s/ Robert D. Pomeroy, Jr.

	Name:	 	Robert D. Pomeroy, Jr.
	Title:	 	Chief Executive Officer

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	 INVESTORS:
  

MAKOWER FAMILY TRUST U/D/T DATED 5/6/97

	
	 /s/ Joshua Makower

	Name:	 	Joshua Makower
	Title:	 	Trustee
	
	 /s/ Joshua Makower

	JOSHUA MAKOWER

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	 INVESTORS:
  

NIAGARA GORGE VENTURE PARTNERS, LLC

	
	 /s/ Scott Friedman

	Name:	 	Scott Friedman
	Title:	 	Manager

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
	
	INVESTORS:
	
	/s/ Vicente Trelles
	VICENTE TRELLES

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 
  

 
	
	 INVESTORS:
  

BARRETT FAMILY TRUST

	
	/s/ Gregory A. Barrett
	Name: Gregory A. Barrett
	Title:   Trustee

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 
			
	 INVESTORS:
  

HUNT-BIOVENTURES, L.P.

		
	Signature: 	 	/s/ Michael T. Bierman
	Name:	 	Michael T. Bierman
	Title:	 	Managing Director

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
 Delphi Ventures VIII, L.P. 

Delphi BioInvestments VIII, L.P. 
 NovaQuest
Pharma Opportunities Fund III, L.P. 
 Medicis Pharmaceutical Corporation 
 Essex Woodlands Health Ventures Fund VIII, L.P. 
 Essex Woodlands Health Ventures Fund VIII-A, L.P.

 Essex Woodlands Health Ventures Fund VIII-B, L.P. 
 Essex Woodlands Health Ventures Fund V, L.P. 
 Essex Capital Corporation 

Shepherd Ventures II, L.P. 
 Technology Partners
Fund VII, LP 
 Technology Partners Affiliates VII, LP 
 CNF Investments II, LLC 
 Kevin Tyler Knight 

Knight Marketing Communications Inc. Defined Benefit Pension Plan 
 Kelsey Margaret Knight 
 Tyler Phillips Knight 

Biotechnology Development Fund IV, L.P. 

Biotechnology Development Fund IV Affiliates, L.P. 
 BDF IV Annex Fund, L.P. 
 Palo Alto Fund II, L.P. 

Niagara Gorge Venture Partners, LLC 
 Dan and
Brenda Browne Living Trust 
 Makower Family Trust U/D/T dated 5/6/97 
 Richard Saxon 
 Donald Ponec 
 David Styka 
 Flea Street Translational, LLC 

L. Daniel Browne 
 Joshua Makower 

Ziv J. Haskal 
 Michael D. Dake, M.D. 

Bobby Purkait 
 Geoffrey D. Rubin 

Kevin Day 
 Barry Katzen, M.D. 

Eberhard Grube, M.D. 
 Amir Houshang Motamedi

 Parivash Motamedi Tabatabai 
 Arash
Padidar 
 Lindsay Machan 
 EXHIBIT A 
 SCHEDULE OF
INVESTORS 

 Biomedical Sciences Investment Fund Pte Ltd 
 BSYE LLC 
 Erulla Partners, LLC 
 PAC-LINK Bio Venture Capital Investment Corporation 
 Asana Holdings, LLC 

Alan L Heller Living Trust 1989 
 Geoffrey and
Annette Grant 
 Legacy Capital Partners 

Greg Tebbe 
 Dyett Family Trust 

Berti Prough Trust 
 Stephen K. Bone and Patricia
L. Bone Trust 
 Gloria G. Coolidge 

Lisa Perry 
 Fitz Partners 

Sheldon Rubin & Rubin, Co-Trustees of the Sheldon Rubin and Ann Rubin 2004 Revocable Intervivos Trust 

Lighthouse Capital Partners IV, L.P. 
 Lighthouse
Capital Partners V, LP 
 Ponec Family Trust dated 01/12/1993 
 Saxon 2002 Family Trust dated 05/25/02 
 Kung Family Trust Dated 02/08/02 

Shah Investors, LP 
 William Facteau and Lydia
Facteau, Trustees of the Facteau Revocable Trust Dated March 3, 2009 
 Douglas Mansfield Petty 

VCA-RTI Partnership 
 Christopher C Dewey

 SVB Financial Group 
 Horizon Credit
I LLC 
 Leader Lending, LLC – Series A 
 Leader Lending, LLC – Series B 
 Vicente Trelles 

Barrett Family Trust 
 Hunt-BioVentures, L.P.

  

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGEEX-10.3

 Exhibit 10.3 
 REVANCE THERAPEUTICS, INC. 

AMENDED AND RESTATED 

2012 EQUITY INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
DECEMBER 12, 2012 
 APPROVED BY THE
STOCKHOLDERS: DECEMBER 13, 2012 
 AMENDED BY
THE BOARD OF DIRECTORS: APRIL 25, 2013 

AMENDMENT APPROVED BY THE STOCKHOLDERS:
APRIL 25, 2013 
 TERMINATION DATE: DECEMBER 11, 2022

 1. GENERAL. 
 (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Revance Therapeutics, Inc. 2002 Equity Incentive Plan (the “Prior
Plan”). Following the Effective Date, no additional stock awards shall be granted under the Prior Plan. Any shares remaining available for issuance pursuant to the exercise of stock awards under the Prior Plan as of the expiration date
of the Prior Plan (the “Prior Plan’s Available Reserve”) shall be available for issuance pursuant to Stock Awards granted hereunder. From and after the Effective Date, all outstanding stock awards granted under the Prior
Plan shall remain subject to the terms of the Prior Plan; provided, however, any shares subject to outstanding stock awards granted under the Prior Plan that expire or terminate for any reason prior to exercise or are forfeited because of the
failure to meet a contingency or condition required to vest such shares (the “Returning Shares”) shall become available for issuance pursuant to Stock Awards granted hereunder. All Stock Awards granted on or after the
Effective Date of this Plan shall be subject to the terms of this Plan. 
 (b) Eligible Stock Award Recipients.
Employees, Directors and Consultants are eligible to receive Stock Awards. 
 (c) Available Stock Awards. The Plan
provides for the grant of the following types of Stock Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock Awards; and (v) Restricted Stock Unit
Awards. 
 (d) Purpose. The Plan, through the granting of Stock Awards, is intended to help the Company secure and retain
the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the
Common Stock. 
 2. ADMINISTRATION. 
 (a) Administration by Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c). 

(b) Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

  
 1. 

 (i) To determine: (A) who will be granted Stock Awards; (B) when and how
each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common
Stock under the Stock Award; (E) the number of shares of Common Stock subject to a Stock Award; and (F) the Fair Market Value applicable to a Stock Award. 
 (ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in
the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.

 (iii) To settle all controversies regarding the Plan and Stock Awards granted under it. 

(iv) To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which cash or
shares of Common Stock may be issued). 
 (v) To suspend or terminate the Plan at any time. Except as otherwise provided
in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection
(viii) below. 
 (vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without
limitation, adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A and/or making the Plan or Stock Awards granted under the Plan compliant with the requirements for Incentive
Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A, subject to the limitations, if any, of applicable law. However, if required by applicable law, and except as provided in
Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan,
(B) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common
Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Stock Awards available for issuance under the Plan. Except as provided in the Plan (including subsection
(viii) below) or a Stock Award Agreement, no amendment of the Plan will impair a Participant’s rights under an outstanding Stock Award unless (1) the Company requests the consent of the affected Participant, and (2) such
Participant consents in writing. 
 (vii) To submit any amendment to the Plan for stockholder approval, including, but
not limited to, amendments to the Plan intended to satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options. 

  
 2. 

 (viii) To approve forms of Stock Award Agreements for use under the Plan and to amend
the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not
subject to Board discretion; provided however, that a Participant’s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such
Participant consents in writing. Notwithstanding the foregoing, (A) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a
whole, does not materially impair the Participant’s rights, and (B) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant’s consent
(1) to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code, (2) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because
it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code, (3) to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A, or (4) to
comply with other applicable laws. 
 (ix) Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan and/or Stock Award Agreements. 
 (x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside
the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike
price of any outstanding Stock Award, (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award,
(4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of shares of Common Stock as the
cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company, or (C) any other action that is treated as a repricing under generally accepted accounting principles. 

(c) Delegation to a Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees.
If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee). Any delegation of administrative
powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the

  
 3. 

 
subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any
time, revest in the Board some or all of the powers previously delegated. 
 (d) Delegation to an Officer. The Board may
delegate to one (1) or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs and, to the extent permitted by applicable law, the terms of such
Stock Awards; and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of
shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently
approved for use by the Committee or the Board, unless otherwise provided for in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also
as a Director) to determine the Fair Market Value pursuant to Section 13(t) below. 
 (e) Effect of Board’s
Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 

3. SHARES SUBJECT TO THE PLAN. 

(a) Share Reserve. 
 (i) Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards beginning on
the Effective Date shall not exceed 6,535,107 shares (the “Share Reserve”), which number is the sum of (A) the number of shares subject to the Prior Plan’s Available Reserve (494,810) plus (B) an
additional number of shares which consists of the Returning Shares, if any, as such shares become available from time to time in an aggregate amount not to exceed 6,040,297 shares. 

(ii) For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be
issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). 
 (b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been
issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for
issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant,
then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in 

  
 4. 

 
satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.

 (c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be equal to two (2) times the Share Reserve number set forth under Section 3(a)(i) above.

 (d) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common
Stock, including shares repurchased by the Company on the open market or otherwise. 
 4. ELIGIBILITY. 

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a
“parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and
Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless
(i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), or
(ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A. 

(b) Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of
such Option is at least one hundred ten percent (110%) of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. 

(c) Consultants. A Consultant will not be eligible for the grant of a Stock Award if, at the time of grant, either the offer or
sale of the Company’s securities to such Consultant is not exempt under Rule 701 (i) because of the nature of the services that the Consultant is providing to the Company, (ii) because the Consultant is not a natural person, or
(iii) because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the
securities laws of all other relevant jurisdictions. 
 5. PROVISIONS RELATING TO
OPTIONS AND STOCK APPRECIATION RIGHTS. 
 Each
Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates
are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an
Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion 

  
 5. 

 
thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Stock Award Agreement will conform to (through
incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions: 
 (a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten (10) years from the date of its
grant or such shorter period specified in the Stock Award Agreement. 
 (b) Exercise Price. Subject to the provisions of
Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the
Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock
Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A and, if applicable,
Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. 
 (c) Purchase Price
for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of
payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the
Company to use a particular method of payment. The permitted methods of payment are as follows: 
 (i) by cash, check,
bank draft or money order payable to the Company; 
 (ii) pursuant to a program developed under Regulation T as
promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price
to the Company from the sales proceeds; 
 (iii) by delivery to the Company (either by actual delivery or attestation) of
shares of Common Stock; 
 (iv) if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement
pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that
the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no
longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to 

  
 6. 

 
the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; 

(v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that interest will
compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of the Code, and
(B) the classification of the Option as a liability for financial accounting purposes; or 
 (vi) in any other form
of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement. 
 (d)
Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The
appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the
number of Common Stock equivalents in which the Participant is vested under such SAR (and with respect to which the Participant is exercising the SAR on such date), over (B) the strike price. The appreciation distribution may be paid in Common
Stock, in cash, in any combination of Common Stock or cash, or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such SAR. 

(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of
Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply: 

(i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution
(and pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable
tax and securities laws. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. 
 (ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official
marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such
transfer. 
 (iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a
Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death 

  
 7. 

 
of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a
designation, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit
designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws. 
 (f) Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The
Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting
provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. 

(g) Termination of Continuous Service. Except as otherwise provided in the applicable Option Agreement, Stock Appreciation Right
Agreement, or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or
her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date three (3) months
following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Option Agreement or Stock Appreciation Right Agreement which period will not be less than thirty (30) days
if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Option Agreement or Stock Appreciation Right Agreement. If, after
termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(h) Extension of Termination Date. Except as otherwise provided in the applicable Option Agreement, Stock Appreciation Right
Agreement, or other agreement between the Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death
or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the
expiration of a total period of three (3) months (that need not be consecutive) after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such
registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Option Agreement or Stock Appreciation Right Agreement. In addition, unless otherwise provided in a Participant’s applicable
Option Agreement or Stock Appreciation Right Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the
Company’s insider trading policy, then the Option or SAR will terminate on the 

  
 8. 

 
earlier of (i) the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s
Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set
forth in the applicable Option Agreement or Stock Appreciation Right Agreement. 
 (i) Disability of Participant. Except
as otherwise provided in the applicable Option Agreement, Stock Appreciation Right Agreement, or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s
Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the
earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the applicable Option Agreement or Stock Appreciation Right Agreement, which period will not be
less than six (6) months if necessary to comply with applicable laws), and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Option Agreement or Stock Appreciation Right Agreement. If, after
termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(j) Death of Participant. Except as otherwise provided in the applicable Option Agreement, Stock Appreciation Right Agreement or
other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the
applicable Option Agreement or Stock Appreciation Right Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the
Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the
Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the applicable Option
Agreement or Stock Appreciation Right Agreement, which period will not be less than six (6) months if necessary to comply with applicable laws), and (ii) the expiration of the term of such Option or SAR as set forth in the applicable
Option Agreement or Stock Appreciation Right Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(k) Termination for Cause. Except as explicitly provided otherwise in a Participant’s applicable Option Agreement, Stock
Appreciation Right Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such
Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. 

  
 9. 

 (l) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a
non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6) months following the date of grant of the Option or SAR
(although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such
Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s applicable Option Agreement or Stock
Appreciation Right Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs
may be exercised earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt Employee in connection with the exercise or vesting of an Option or SAR will be
exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt Employee in connection with the exercise, vesting or
issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award
Agreements. 
 (m) Early Exercise of Options. An Option may, but need not, include a provision whereby the Optionholder
may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the Option. Subject to the
“Repurchase Limitation” in Section 8(m), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of the Company or to any other restriction the Board determines to be appropriate. Provided
that the “Repurchase Limitation” in Section 8(m) is not violated, the Company will not be required to exercise its repurchase right until at least six (6) months (or such longer or shorter period of time required to
avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement. 

(n) Right of Repurchase. Subject to the “Repurchase Limitation” in Section 8(m), the Option or SAR may include
a provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR. 

(o) Right of First Refusal. The Option or SAR may include a provision whereby the Company may elect to exercise a right of first
refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject to the
“Repurchase Limitation” in Section 8(m). Except as expressly provided in this Section 5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of
the Company. 

  
 10.

 6. PROVISIONS OF STOCK AWARDS
OTHER THAN OPTIONS AND SARS. 
 (a) Restricted
Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of
Common Stock may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form
and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted
Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order
payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under
applicable law. 
 (ii) Vesting. Subject to the “Repurchase Limitation” in Section 8(m), shares of
Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. 

(iii) Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may
receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award
Agreement. 
 (iv) Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement
will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock
Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. 
 (v) Dividends. A Restricted
Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. 

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and
conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each
Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: 

  
 11.

 (i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board
will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock
subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions
to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 
 (iii) Payment. A
Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award
Agreement. 
 (iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it
deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.

 (v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a
Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the
Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the
underlying Restricted Stock Unit Award Agreement to which they relate. 
 (vi) Termination of Participant’s Continuous
Service. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.

 (vii) Compliance with Section 409A. Notwithstanding anything to the contrary set forth herein, any Restricted
Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A shall contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of Section 409A. Such restrictions,
if any, shall be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Stock that
is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed pre-determined schedule. 

  
 12.

 7. COVENANTS OF THE COMPANY. 

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required
to satisfy then-outstanding Stock Awards. 
 (b) Securities Law Compliance. The Company will seek to obtain from each
regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking
will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to
obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and
sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if
such grant or issuance would be in violation of any applicable securities law. 
 (c) No Obligation to Notify or Minimize
Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder
of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.

 8. MISCELLANEOUS. 
 (a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company. 

(b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a grant by the Company of a Stock Award to
any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received
or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of
shares) that are inconsistent with those in the Stock Award Agreement as a result of a clerical error in the papering of the Stock Award Agreement, the corporate records will control and the Participant will have no legally binding right to the
incorrect term in the Stock Award Agreement. 
 (c) Stockholder Rights. No Participant will be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the

  
 13.

 
issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to the Stock Award has been entered into the books and
records of the Company. 
 (d) No Employment or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or
any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award
was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, including, but not limited to, Cause, (ii) the service of a Consultant
pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the
state in which the Company or the Affiliate is incorporated, as the case may be. 
 (e) Change in Time Commitment. In the
event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the
Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number
of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment
schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended. 

(f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of
Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000) (or
such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not
comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 
 (g) Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to
the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business
matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the
Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given
pursuant 

  
 14.

 
to such requirements, will be inoperative if (i) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently
effective registration statement under the Securities Act, or (ii) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable
securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not
limited to, legends restricting the transfer of the Common Stock. 
 (h) Withholding Obligations. Unless prohibited by
the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means (in addition to the Company’s right to
withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued
or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount
as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the
Participant; or (v) by such other method as may be set forth in the Stock Award Agreement. 
 (i) Electronic
Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company
to which the Participant has access). 
 (j) Deferrals. To the extent permitted by applicable law, the Board, in its sole
discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to
be made by Participants. Deferrals by Participants will be made in accordance with Section 409A. Consistent with Section 409A, the Board may provide for distributions while a Participant is still an employee or otherwise providing services
to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous
Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 
 (k) Compliance with Section 409A. To the extent that the Board determines that any Stock Award granted hereunder is subject to Section 409A, the Stock Award Agreement evidencing such
Stock Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be interpreted in accordance with
Section 409A. 
 (l) Compliance with Exemption Provided by Rule 12h-1(f). If at the end of the Company’s most
recently completed fiscal year: (i) the aggregate of the number of persons who 

  
 15.

 
hold outstanding compensatory employee stock options to purchase shares of Common Stock granted pursuant to the Plan or otherwise (such persons, “Holders of Options”)
equals or exceeds five hundred (500); and (ii) the Company’s assets exceed $10 million, then the following restrictions will apply during any period during which the Company does not have a class of its securities registered under
Section 12 of the Exchange Act and is not required to file reports under Section 15(d) of the Exchange Act: (A) the Options and, prior to exercise, the shares of Common Stock to be issued on exercise of the Options may not be
transferred until the Company is no longer relying on the exemption provided by Rule 12h-1(f) promulgated under the Exchange Act (“Rule 12h-1(f)”), except: (1) as permitted by Rule 701(c) promulgated under the Securities
Act, (2) to a guardian upon the disability of the Holder of Options, or (3) to an executor upon the death of the Holder of Options (collectively, the “Permitted Transferees”); provided, however, the following
transfers are permitted: (i) transfers by Holders of Options to the Company; and (ii) transfers in connection with a change of control or other acquisition involving the Company, if following such transaction, the Options no longer remain
outstanding and the Company is no longer relying on the exemption provided by Rule 12h-1(f); provided further, that any Permitted Transferees may not further transfer the Options; (B) except as otherwise provided in (A) above, the
Options and shares of Common Stock issuable on exercise of the Options are restricted as to any pledge, hypothecation, or other transfer, including any short position, any “put equivalent position” as defined by Rule 16a-1(h) promulgated
under the Exchange Act, or any “call equivalent position” as defined by Rule 16a-1(b) promulgated under the Exchange Act by Holders of Options prior to exercise of an Option until the Company is no longer relying on the exemption provided
by Rule 12h-1(f); and (C) at any time that the Company is relying on the exemption provided by Rule 12h-1(f), the Company will deliver to Holders of Options (whether by physical or electronic delivery or written notice of the availability of
the information on an internet site) the information required by Rule 701(e)(3), (4), and (5) promulgated under the Securities Act every six (6) months, including financial statements that are not more than one hundred eighty
(180) days old; provided, however, that the Company may condition the delivery of such information upon the Holder of Options’ agreement to maintain its confidentiality. 

(m) Repurchase Limitation. The terms of any repurchase right will be specified in the Stock Award Agreement. The repurchase price
for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i) the Fair Market Value of the shares of
Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company will not exercise its repurchase right until at least six (6) months (or such longer or shorter period of time necessary to avoid
classification of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. 

9. ADJUSTMENTS UPON CHANGES IN COMMON STOCK;
OTHER CORPORATE EVENTS. 
 (a) Capitalization Adjustments. In the event
of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a); (ii) the class(es) and maximum number of
securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c); and (iii) the class(es) and number of securities and price per share of stock subject

  
 16.

 
to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive. 

(b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or
liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately
prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact
that the holder of such Stock Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. 
 (c) Corporate Transaction. The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any
other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the event of a Corporate Transaction, then, notwithstanding any other
provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction: 

(i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate
Transaction); 
 (ii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect
of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 
 (iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such
Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective date of the Corporate Transaction), with such Stock Award terminating if not exercised
(if applicable) at or prior to the effective time of the Corporate Transaction; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of exercise before the effective date of a Corporate
Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction; 
 (iv) arrange for the
lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award; 

  
 17.

 (v) cancel or arrange for the cancellation of the Stock Award, to the extent not
vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and 

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the
property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For
clarity, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s
Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. 

The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board
may take different actions with respect to the vested and unvested portions of a Stock Award. 
 (d) Change in Control. A
Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between
the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur. 
 10.
PLAN TERM; EARLIER TERMINATION OR SUSPENSION OF THE PLAN. 

(a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will
automatically terminate on the day before the tenth (10th) anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be
granted under the Plan while the Plan is suspended or after it is terminated. 
 (b) No Impairment of Rights. Suspension
or termination of the Plan will not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan. 

11. EFFECTIVE DATE OF PLAN. 

This Plan will become effective on the Effective Date. 
 12. CHOICE OF LAW. 
 The laws
of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules. 
 13. DEFINITIONS. As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

  
 18.

 (a) “Affiliate” means, at the time of determination, any
“parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “majority-owned
subsidiary” status is determined within the foregoing definition. 
 (b) “Board” means the
Board of Directors of the Company. 
 (c) “Capitalization Adjustment” means any change that is
made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. 
 (d)
“Cause” will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant,
the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such
Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the
Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The
determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was
terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. 

(e) “Change in Control” means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) any Exchange Act Person becomes the Owner, directly or
indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an
investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance
of equity securities or (C) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the 

  
 19.

 
designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares
outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change
in Control will be deemed to occur; 
 (ii) there is consummated a merger, consolidation or similar transaction involving
(directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than
fifty percent (50%) of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the
outstanding voting securities of the Company immediately prior to such transaction; 
 (iii) the stockholders of the
Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent corporation; or 

(iv) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated
assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of
the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease,
license or other disposition. 
 Notwithstanding the foregoing definition or any other provision of this Plan, (A) the term Change in
Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written
agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous
term is set forth in such an individual written agreement, the foregoing definition will apply. 
 (f)
“Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. 
 (g) “Committee” means a committee of one (1) or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c). 

  
 20.

 (h) “Common Stock” means the common stock of the Company.

 (i) “Common Stock” means the common stock of the Company. 

(j) “Company” means Revance Therapeutics, Inc., a Delaware corporation. 

(k) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an
Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or
payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.  
 (l) “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or
terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the Entity for which the Participant renders such service, provided that there is no
interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services
ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change
in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that
party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other
personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as
may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. 

(m) “Corporate Transaction” means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) a sale or other disposition of all or substantially all,
as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 
 (ii)
a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company. Notwithstanding the foregoing, a Corporate Transaction will not be deemed to occur on account of the acquisition of securities of the
Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through
the issuance of equity securities or through the cancellation or conversation (or combination thereof) of indebtedness of the Company; 

  
 21.

 (iii) a merger, consolidation or similar transaction following which the Company is
not the surviving corporation; or 
 (iv) a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. 
 (n) “Director” means a member of the
Board. 
 (o) “Disability” means, with respect to a Participant, the inability of such
Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less
than twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(C)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(p) “Effective Date” means the effective date of this Plan, which is the earlier of (i) the date that
this Plan is first approved by the Company’s stockholders, and (ii) the date this Plan is adopted by the Board. 

(q) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a
Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan. 
 (r) “Entity” means a corporation, partnership, limited liability company or other entity. 
 (s) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

(t) “Exchange Act Person” means any natural person, Entity or “group” (within the meaning of
Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of
the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities,
(iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning
of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the
Company’s then outstanding securities. 
 (u) “Fair Market Value” means, as of any date, the
value of the Common Stock determined by the Board in compliance with Section 409A or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

  
 22.

 (v) “Incentive Stock Option” means an option granted pursuant
to Section 5 of the Plan that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 
 (w) “Nonstatutory Stock Option” means any option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option. 

(x) “Officer” means any person designated by the Company as an officer. 

(y) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common
Stock granted pursuant to the Plan. 
 (z) “Option Agreement” means a written agreement between
the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 
 (aa) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. 

(bb) “Other Stock Award” means an award based in whole or in part by reference to the Common Stock which
is granted pursuant to the terms and conditions of Section 6(c). 
 (cc) “Other Stock Award
Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and
conditions of the Plan. 
 (dd) “Own,” “Owned,”
“Owner,” “Ownership” means a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of
securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such
securities. 
 (ee) “Participant” means a person to whom a Stock Award is granted pursuant to the
Plan or, if applicable, such other person who holds an outstanding Stock Award. 
 (ff) “Plan”
means this Revance Therapeutics, Inc. Amended and Restated 2012 Equity Incentive Plan. 
 (gg) “Restricted
Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a). 
 (hh) “Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a
Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

  
 23.

 (ii) “Restricted Stock Unit Award” means a right to receive
shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b). 
 (jj)
“Restricted Stock Unit Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each
Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. 
 (kk) “Rule
405” means Rule 405 promulgated under the Securities Act. 
 (ll) “Rule 701” means
Rule 701 promulgated under the Securities Act. 
 (mm) “Securities Act” means the Securities Act
of 1933, as amended. 
 (nn) “Section 409A” means Section 409A of the Code and the
regulations and other guidance thereunder and any state law of similar effect. 
 (oo) “Stock Appreciation
Right” or “SAR” means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5. 

(pp) “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a
Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan. 

(qq) “Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive
Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. 
 (rr) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award
Agreement will be subject to the terms and conditions of the Plan. 
 (ss) “Subsidiary” means,
with respect to the Company, (i) any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of
whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any
partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). 

(tt) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to
Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Affiliate. 

  
 24.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]